Phase 2 N=151 A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
Plaque Psoriasis
Primary: Clinical Response of Success — 6; 4; 6; 1 Participants — p=0.3571
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,000 Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
Tuberculosis · HIV Infections
Primary: Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause — 0.6506; 0.6736 Events per 100 person-years
Phase 2 N=6 Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
Fragile X-associated Tremor/Ataxia Syndrome
Primary: California Verbal Learning Test II (CVLT2) Trial 1-5 Free Recall Total Raw Score — 34.0; 33.5 score on a scale
Phase 2 N=16 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
Plaque Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 0; 10; 0 Participants
Phase 2 N=141 Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
N/A N=111 Decisional Capacity and Informed Consent in Fragile X Syndrome
Fragile X Syndrome (FXS)
Primary: Decisional Capacity - Understanding Score — 74.4; 75.1 percentage of understanding — p=0.89
Phase 3 N=1,130 Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
Migraine
Primary: Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12-Week Period After the First Dose of Study Drug — -2.5…
Phase 3 N=371 Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961
Phase 2 N=30 FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
Chronic Lymphocytic Leukemia
Primary: Clinical Response Rate at 3 Months — 29 Participants
Phase 3 N=373 Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis — 41; 43 Participants — p=0.4557
Phase 4 N=42 Nebivolol and the Endothelin (ET)-1 System
Prehypertension · Hypertension
Primary: Systolic Blood Pressure — 144; 126; 140; 125 mmHg
N/A N=218 CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy
Aging
Primary: Change in Core Body Temperature, Baseline to 12 Months — -0.05; -0.03 degrees Celsius — p=0.70
Phase 4 N=3,630 Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
COPD · Chronic Obstructive Pulmonary Disease · Moderate to Very Severe COPD
Primary: Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Subject Per Year During the First Year of Treatment — 0.44; 0.57 Events per…
N/A N=61 Clinical Evaluation Of MP26 Features in Adults
Brain Imaging · Whole Body Imaging
Primary: Diagnostic Image Quality — 4.4; 3.9 scores on a scale
Phase 4 N=246 TXA vs. Amicar in Total Knee and Hip Arthroplasty
Blood Loss · Hip Arthritis · Knee Arthritis
Primary: Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge) — 934.1; 948.7; 660.6; 891.2 milliliters — p=<0.05